A Phase 3, multicenter, open-label extension study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with psoriatic arthritis (PsA)

Status

Not yet recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-522471-28-00

Enrollment

123

Registered

2026-02-25

Start date

Unknown

Completion date

Unknown

Last updated

2026-02-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

psoriatic arthritis (PsA)

Brief summary

Treatment-emergent adverse events (TEAEs), Serious adverse events (SAEs), TEAEs leading to study withdrawal, Adverse events of special interest (AESIs), Vital signs, and electrocardiogram (ECG) results, Abnormal laboratory parameters (hematology, clinical chemistry)

Interventions

DRUGSonelokimab

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Treatment-emergent adverse events (TEAEs), Serious adverse events (SAEs), TEAEs leading to study withdrawal, Adverse events of special interest (AESIs), Vital signs, and electrocardiogram (ECG) results, Abnormal laboratory parameters (hematology, clinical chemistry)	—

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 27, 2026